Lung Cancer

The FDA has granted fast track designation to PT217 for patients with extensive stage small cell lung cancer with disease progression.

Jacob Sands, MD, shares updated data from the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan versus docetaxel in non-squamous non-small cell lung cancer recently presented at the 2024 European Lung Cancer Congress (ELCC).

The FDA has granted breakthrough therapy designation to sunvozertinib for patients with locally advanced or metastatic NSCLC with an EGFR exon 20 insertion mutation.

Neel P. Chudgar, MD, discusses his presentation on resectability in non–small cell lung cancer at the 21st Annual Winter Lung Cancer Conference®.

Jaime Schneider, MD, PhD, discusses considerations for patients with EGFR-mutant non–small cell lung cancer that progresses on osimertinib.

Durvalumab monotherapy showed clinical benefit in limited-stage small cell lung cancer, according to data from the phase 3 ADRIATIC trial.

Data from the phase 2 KICKSTART trial of tomivosertib plus pembrolizumab do not support the combination's use in patients with non–small cell lung cancer.

Ben Creelan, MD, discusses survival outcomes with cemiplimab in patients with squamous non–small cell lung cancer.

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

Neel P. Chudgar, MD, discusses considerations for determining lung cancer resection eligibility and how neoadjuvant therapy may affect resectability.

Paul K. Paik, MD, discusses the FDA approval of tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Adagrasib improved progression-free survival and objective response rates vs docetaxel in pretreated KRAS G12C–mutant non–small cell lung cancer.

Raj Singh, MD, discusses treating patients with lung cancer with CNS metastases.

China’s NMPA has accepted an sNDA for approval of savolitinib for treatment-naive locally advanced/metastatic NSCLC with MET exon 14 skipping alterations.

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.

TTFields plus supportive care improved time to intracranial progression in patients with brain metastases from non–small cell lung cancer.

Osimertinib plus chemotherapy confers superior post-progression survival outcomes vs osimertinib alone in patients with EGFR-mutated NSCLC.

Anlotinib plus etoposide, carboplatin, and placebo improved PFS vs etoposide plus carboplatin and 2 placebos in first-line ES-SCLC.

Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Pembrolizumab plus olaparib as first-line maintenance therapy did not improve survival in patients with metastatic nonsquamous non–small cell lung cancer.

Becotarug plus osimertinib elicited responses with manageable safety in patients with non–small cell lung cancer and EGFR exon 12 insertion mutations.